PURPOSE: The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. MATERIALS AND METHODS: This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year. RESULTS: No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power. CONCLUSIONS:Men receivingandrogen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.
RCT Entities:
PURPOSE: The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. MATERIALS AND METHODS: This is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year. RESULTS: No statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power. CONCLUSIONS:Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.
Authors: P Szulc; F Munoz; B Claustrat; P Garnero; F Marchand; F Duboeuf; P D Delmas Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: S A Stoch; R A Parker; L Chen; G Bubley; Y J Ko; A Vincelette; S L Greenspan Journal: J Clin Endocrinol Metab Date: 2001-06 Impact factor: 5.958
Authors: M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein Journal: N Engl J Med Date: 2001-09-27 Impact factor: 91.245
Authors: Dan Mellström; Liesbeth Vandenput; Hans Mallmin; Anna H Holmberg; Mattias Lorentzon; Anders Odén; Helena Johansson; Eric S Orwoll; Fernand Labrie; Magnus K Karlsson; Osten Ljunggren; Claes Ohlsson Journal: J Bone Miner Res Date: 2008-10 Impact factor: 6.741
Authors: Christian Meier; Tuan V Nguyen; David J Handelsman; Christian Schindler; Mark M Kushnir; Alan L Rockwood; A Wayne Meikle; Jacqueline R Center; John A Eisman; Markus J Seibel Journal: Arch Intern Med Date: 2008-01-14
Authors: Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan Journal: JAMA Date: 2003-06-25 Impact factor: 56.272
Authors: Hirotaka Miyashita; Sera Satoi; Christina Cruz; Se-Min Kim; Vaibhav G Patel Journal: Support Care Cancer Date: 2021-08-15 Impact factor: 3.603
Authors: Andrea Dueregger; Isabel Heidegger; Philipp Ofer; Bernhard Perktold; Reinhold Ramoner; Helmut Klocker; Iris E Eder Journal: Nutrients Date: 2014-10-21 Impact factor: 5.717
Authors: Luisella Cianferotti; Francesco Bertoldo; Marco Carini; John A Kanis; Alberto Lapini; Nicola Longo; Giuseppe Martorana; Vincenzo Mirone; Jean-Yves Reginster; Rene Rizzoli; Maria Luisa Brandi Journal: Oncotarget Date: 2017-05-18